Personalised medicine is dependent on our ability to visualise the molecular variability of diseases, leading to the design of effective and tailored therapies. Current imaging methods focus primarily on the detection of single analytes, which is unable to capture the molecular complexity and heterogeneity of biological environments. The objective of this work is to develop new technology in the form of multi-analyte fluorescent probes to more reliably visualise the molecular diversity of living systems. These tools will be used to unravel the poorly understood biochemical heterogeneity of prostate cancer and thus help improve diagnostic reliability and treatment efficacy of the disease. The new technology can also be applied straightforwardly to the search for new biomarkers for other diseases (e.g. other cancers, neurodegeneration and obesity), and as such may exert significant impact on medical research and clinical practice.